FDA Grants Priority Review for New Leukemia Option
The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug’s developer.
Blinatumomab Gets Full FDA Approval for B-Cell Precursor ALL
The FDA has expanded the approval of blinatumomab (Blincyto) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.
Dasatinib Is Safe, Effective in Pediatric Chronic Myeloid Leukemia
Dasatinib was safe and effective in pediatric patients with chronic myeloid leukemia, according to a new study, establishing the agent as a new standard of care for this population.
Protocol Improvements Reduce Health Conditions in Childhood Cancer Survivors
Significant improvements in treatment protocols have reduced the incidence of serious chronic late health effects in survivors of childhood cancer treatment.
MRD Status Indicated Therapeutic Benefit in Pediatric, Adult ALL
There is considerable value in having achieved a minimal residual disease negativity for pediatric and adult patients with acute lymphoblastic leukemia.
Inflammation Linked to Cognitive Difficulties in Childhood ALL Survivors
Female survivors of childhood acute lymphoblastic leukemia were at risk for neurocognitive impairment and were more susceptible to the effects of sleep disturbance and fatigue compared with their male counterparts.
Second Primary Malignancies More Deadly in Younger Cancer Patients
Younger cancer survivors experience worse survival outcomes following a second primary cancer diagnosis than their older counterparts, according to a recent study.
By clicking Accept, you agree to become a member of the UBM Medica Community.